FindTrial
Sign In

Examination on the differences of the symptoms which should be given priority to treatment from the perspective of major depressive disorder patients vs their physicians

Examination on the differences of the symptoms which should be given priority to treatment from the perspective of major depressive disorder patients vs their physicians - Examination on the differences of the symptoms which should be given priority to treatment from the perspective of major depressive disorder patients vs their physicians

Status
Active, not recruiting
Phases
Unknown
Study type
Unknown
Source
JPRN
Registry ID
JPRN-UMIN000039967
Enrollment
2300
Registered
2020-03-27
Start date
2020-03-30
Completion date
Unknown
Last updated
2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Major depressive disorder (MDD)

Interventions

None listed

Sponsors

Takeda Pharmaceutical Company Limited.
Lead Sponsor
Lundbeck Japan K.K.
Collaborator

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: [Survey in patients] 1)Patients have ever been diagnosed with depression. 2) Patients who are currently using a medication or not currently use but have been used medication to treat depression in the past 3 months. 3) Patients who are older than 19 years or younger than 66 years old. 4) Patients who showed 10 or higher score of PHQ-9 survey in their most severe MDD symptoms in the past. [Survey in physicians] 1)Physicians should be board-certified psychiatrists or psychosomatic internal medical doctors examining more than 40 or more MDD patients per month. 2)Physicians who are currently prescribing antidepressants to more than 75 % of their MDD patients.

Exclusion criteria

Exclusion criteria: [Survey in patients] 1) Physicians who are employed by a pharmaceutical company or marketing agency. 2) Patients who show 9 or less score of PHQ-9 survey in their most severe MDD symptoms in the past. [Survey in physicians] 1)Physicians themselves or their relatives are employed by a pharmaceutical company or marketing agency.

Design outcomes

Primary

MeasureTime frame
[Survey in patients] Measurement item:38 questions [Survey in physicians] Measurement item: 21 questions—

Countries

Japan

Contacts

Public ContactTatsuya Hoshino

Takeda Pharmaceutical Company Limited. Japan Medical Office

tatsuya.hoshino@takeda.com03-3242-1256

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026